Soluble SIGLEC5: A New Prognosis Marker in Colorectal Cancer Patients

Montalbán-Hernández, Karla; Cantero-Cid, Ramón; Lozano-Rodríguez, Roberto; Pascual-Iglesias, Alejandro; Avendaño-Ortíz, José; Casalvilla-Dueñas, José Carlos; Bonel-Pérez, Gloria C.; Guevara, Julio Guevara; Marcano, Cristóbal; Barragán, Cristina; Valentín, Jaime; Fresno, Carlos del; Aguirre, Luis A.; López-Collazo, Eduardo

doi:10.3390/cancers13153896

Cited by 8 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found no direct link between IL12A/B with ovarian cancer, although pre-activation with IL-12 in ovarian cancer cell lines is shown to improve the efficacy of natural killer cell immunotherapy [ 41 ]. Finally, SIGLEC5 is suggested as a prognostic marker for colorectal cancer [ 42 ] but we found no previously published association with ovarian cancer.…”

Section: Discussioncontrasting

confidence: 71%

Next Generation Plasma Proteomics Identifies High-Precision Biomarker Candidates for Ovarian Cancer

Gyllensten

Hedlund-Lindberg

Svensson

et al. 2022

Cancers

View full text Add to dashboard Cite

Background: Ovarian cancer is the eighth most common cancer among women and has a 5-year survival of only 30–50%. The survival is close to 90% for patients in stage I but only 20% for patients in stage IV. The presently available biomarkers have insufficient sensitivity and specificity for early detection and there is an urgent need to identify novel biomarkers. Methods: We employed the Explore PEA technology for high-precision analysis of 1463 plasma proteins and conducted a discovery and replication study using two clinical cohorts of previously untreated patients with benign or malignant ovarian tumours (N = 111 and N = 37). Results: The discovery analysis identified 32 proteins that had significantly higher levels in malignant cases as compared to benign diagnoses, and for 28 of these, the association was replicated in the second cohort. Multivariate modelling identified three highly accurate models based on 4 to 7 proteins each for separating benign tumours from early-stage and/or late-stage ovarian cancers, all with AUCs above 0.96 in the replication cohort. We also developed a model for separating the early-stage from the late-stage achieving an AUC of 0.81 in the replication cohort. These models were based on eleven proteins in total (ALPP, CXCL8, DPY30, IL6, IL12, KRT19, PAEP, TSPAN1, SIGLEC5, VTCN1, and WFDC2), notably without MUCIN-16. The majority of the associated proteins have been connected to ovarian cancer but not identified as potential biomarkers. Conclusions: The results show the ability of using high-precision proteomics for the identification of novel plasma protein biomarker candidates for the early detection of ovarian cancer.

show abstract

Section: Discussioncontrasting

confidence: 71%

Next Generation Plasma Proteomics Identifies High-Precision Biomarker Candidates for Ovarian Cancer

Gyllensten

Hedlund-Lindberg

Svensson

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

“…This prospective patient cohort had a short follow-up time that did not allow to monitor enough metastatic events. Nonetheless, since sSIGLEC5 levels have been recently associated with disease prognosis in CRC [22], the positive correlation found between THC counts and sSIGLEC5 levels indicates a potential correlation between THC numbers in circulation and patient prognosis in CRC. Finally, considering the previously addressed relationship between immune evasion properties in THCs and SIGLEC5, we moved on to analyse the correlation between soluble SIGLEC5 (sSIGLEC5) levels and THC counts in circulation.…”

Section: Thc-specific Signature Is Present In Circulation Of Colorect...mentioning

confidence: 94%

Colorectal Cancer Stem Cells Fuse with Monocytes to Form Tumour Hybrid Cells with the Ability to Migrate and Evade the Immune System

Montalbán-Hernández¹,

Cantero-Cid

Casalvilla-Dueñas³

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

Background: The cancer cell fusion theory could be one of the best explanations for the metastasis from primary tumours. Methods: Herein, we co-cultured colorectal cancer (CRC) stem cells with human monocytes and analysed the properties of the generated tumour hybrid cells (THCs). The presence of THCs in the bloodstream together with samples from primary and metastatic lesions and their clinical correlations were evaluated in CRC patients and were detected by both FACS and immunofluorescence methods. Additionally, the role of SIGLEC5 as an immune evasion molecule in colorectal cancer was evaluated. Results: Our data demonstrated the generation of THCs after the in vitro co-culture of CRC stem cells and monocytes. These cells, defined as CD45+CD14+EpCAM+, showed enhanced migratory and proliferative abilities. The THC-specific cell surface signature allows identification in matched primary tumour tissues and metastases as well as in the bloodstream from patients with CRC, thus functioning as a biomarker. Moreover, SIG-LEC5 expression on in vitro generated THCs has shown to be involved in the mechanism for immune evasion. Additionally, sSIGLEC5 levels correlated with THC numbers in the prospective cohort of patients. Conclusions: Our results indicate the generation of a hybrid entity after the in vitro co-culture between CRC stem cells and human monocytes. Moreover, THC numbers present in patients are related to both prognosis and the later spread of metastases in CRC patients.

show abstract

“…In our study, we found that expression of both Siglec-3 (CD33) and Siglec-5 (CD170) increased after corticosteroid treatment. These two receptors have recently been described as having immune checkpoint roles and usefulness as prognosis markers in different contexts [ 53 , 54 , 55 , 56 ]. Concerning lymphoid cells, we want to highlight the B7H5 (VISTA) increment in NK, CD8 + and CD4 + cells after corticosteroid treatment.…”

Section: Discussionmentioning

confidence: 99%

Differential Immune Checkpoint and Ig-like V-Type Receptor Profiles in COVID-19: Associations with Severity and Treatment

Lozano-Rodríguez

Terrón-Arcos

Lopez³

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

Identifying patients’ immune system status has become critical to managing SARS-CoV-2 infection and avoiding the appearance of secondary infections during a hospital stay. Despite the high volume of research, robust severity and outcome markers are still lacking in COVID-19. We recruited 87 COVID-19 patients and analyzed, by unbiased automated software, 356 parameters at baseline emergency department admission including: high depth immune phenotyping and immune checkpoint expression by spectral flow cytometry, cytokines and other soluble molecules in plasma as well as routine clinical variables. We identified 69 baseline alterations in the expression of immune checkpoints, Ig-like V type receptors and other immune population markers associated with severity (O2 requirement). Thirty-four changes in these markers/populations were associated with secondary infection appearance. In addition, through a longitudinal sample collection, we described the changes which take place in the immune system of COVID-19 patients during secondary infections and in response to corticosteroid treatment. Our study provides information about immune checkpoint molecules and other less-studied receptors with Ig-like V-type domains such as CD108, CD226, HVEM (CD270), B7H3 (CD276), B7H5 (VISTA) and GITR (CD357), defining these as novel interesting molecules in severe and corticosteroids-treated acute infections.

show abstract

Soluble SIGLEC5: A New Prognosis Marker in Colorectal Cancer Patients

Cited by 8 publications

References 32 publications

Next Generation Plasma Proteomics Identifies High-Precision Biomarker Candidates for Ovarian Cancer

Next Generation Plasma Proteomics Identifies High-Precision Biomarker Candidates for Ovarian Cancer

Colorectal Cancer Stem Cells Fuse with Monocytes to Form Tumour Hybrid Cells with the Ability to Migrate and Evade the Immune System

Differential Immune Checkpoint and Ig-like V-Type Receptor Profiles in COVID-19: Associations with Severity and Treatment

Contact Info

Product

Resources

About